US5849719A
(en)
*
|
1993-08-26 |
1998-12-15 |
The Regents Of The University Of California |
Method for treating allergic lung disease
|
US6727230B1
(en)
|
1994-03-25 |
2004-04-27 |
Coley Pharmaceutical Group, Inc. |
Immune stimulation by phosphorothioate oligonucleotide analogs
|
US7935675B1
(en)
|
1994-07-15 |
2011-05-03 |
University Of Iowa Research Foundation |
Immunostimulatory nucleic acid molecules
|
US6429199B1
(en)
|
1994-07-15 |
2002-08-06 |
University Of Iowa Research Foundation |
Immunostimulatory nucleic acid molecules for activating dendritic cells
|
US20030026782A1
(en)
*
|
1995-02-07 |
2003-02-06 |
Arthur M. Krieg |
Immunomodulatory oligonucleotides
|
US6207646B1
(en)
*
|
1994-07-15 |
2001-03-27 |
University Of Iowa Research Foundation |
Immunostimulatory nucleic acid molecules
|
US6239116B1
(en)
*
|
1994-07-15 |
2001-05-29 |
University Of Iowa Research Foundation |
Immunostimulatory nucleic acid molecules
|
US5981501A
(en)
*
|
1995-06-07 |
1999-11-09 |
Inex Pharmaceuticals Corp. |
Methods for encapsulating plasmids in lipid bilayers
|
US7422902B1
(en)
*
|
1995-06-07 |
2008-09-09 |
The University Of British Columbia |
Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
|
AU1463097A
(en)
|
1996-01-04 |
1997-08-01 |
Rican Limited |
Helicobacter pylori bacterioferritin
|
US20030078223A1
(en)
*
|
1996-01-30 |
2003-04-24 |
Eyal Raz |
Compositions and methods for modulating an immune response
|
ATE437943T1
(de)
*
|
1996-01-30 |
2009-08-15 |
Univ California |
Expressionsvektoren, die eine antigen-spezifische immunantwort induzieren, und methoden für ihre verwendung.
|
EP0855184A1
(en)
*
|
1997-01-23 |
1998-07-29 |
Grayson B. Dr. Lipford |
Pharmaceutical composition comprising a polynucleotide and an antigen especially for vaccination
|
US6406705B1
(en)
|
1997-03-10 |
2002-06-18 |
University Of Iowa Research Foundation |
Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
|
WO1998051278A2
(en)
|
1997-05-14 |
1998-11-19 |
Inex Pharmaceuticals Corporation |
High efficiency encapsulation of charged therapeutic agents in lipid vesicles
|
CA2301575C
(en)
|
1997-05-20 |
2003-12-23 |
Ottawa Civic Hospital Loeb Research Institute |
Vectors and methods for immunization or therapeutic protocols
|
DE69819150T3
(de)
|
1997-06-06 |
2007-12-20 |
Dynavax Technologies Corp., San Diego |
Immunstimulierende oligonucleotide, zusammensetzungen davon, und verfahren zur verwendung davon
|
US6589940B1
(en)
|
1997-06-06 |
2003-07-08 |
Dynavax Technologies Corporation |
Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
|
US20040006034A1
(en)
*
|
1998-06-05 |
2004-01-08 |
Eyal Raz |
Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
|
US20030045492A1
(en)
*
|
1997-08-13 |
2003-03-06 |
Tang De-Chu C. |
Vaccination by topical application of recombinant vectors
|
US20030125278A1
(en)
*
|
1997-08-13 |
2003-07-03 |
Tang De-Chu C. |
Immunization of animals by topical applications of a salmonella-based vector
|
US7964192B1
(en)
|
1997-12-02 |
2011-06-21 |
Janssen Alzheimer Immunotherapy |
Prevention and treatment of amyloidgenic disease
|
US20080050367A1
(en)
*
|
1998-04-07 |
2008-02-28 |
Guriq Basi |
Humanized antibodies that recognize beta amyloid peptide
|
US7790856B2
(en)
*
|
1998-04-07 |
2010-09-07 |
Janssen Alzheimer Immunotherapy |
Humanized antibodies that recognize beta amyloid peptide
|
TWI239847B
(en)
*
|
1997-12-02 |
2005-09-21 |
Elan Pharm Inc |
N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
|
US6787523B1
(en)
*
|
1997-12-02 |
2004-09-07 |
Neuralab Limited |
Prevention and treatment of amyloidogenic disease
|
DE69935507T2
(de)
*
|
1998-04-03 |
2007-12-06 |
University Of Iowa Research Foundation |
Verfahren und produkte zur stimulierung des immunsystems mittels immunotherapeutischer oligonukleotide und zytokine
|
CA2328406A1
(en)
*
|
1998-05-14 |
1999-11-18 |
Hermann Wagner |
Methods for regulating hematopoiesis using cpg-oligonucleotides
|
WO1999059578A1
(en)
|
1998-05-19 |
1999-11-25 |
Research Development Foundation |
Triterpene compositions and methods for use thereof
|
SI1077722T1
(sl)
*
|
1998-05-22 |
2007-02-28 |
Ottawa Health Research Inst |
Metode in produkti za induciranje sluznicne imunosti
|
US20020106635A1
(en)
*
|
1998-05-27 |
2002-08-08 |
Bruce Freimark |
Cytokine resistant cytomegalovirus promoter mutants and related products and methods
|
US20030022854A1
(en)
*
|
1998-06-25 |
2003-01-30 |
Dow Steven W. |
Vaccines using nucleic acid-lipid complexes
|
US20040247662A1
(en)
*
|
1998-06-25 |
2004-12-09 |
Dow Steven W. |
Systemic immune activation method using nucleic acid-lipid complexes
|
US6693086B1
(en)
*
|
1998-06-25 |
2004-02-17 |
National Jewish Medical And Research Center |
Systemic immune activation method using nucleic acid-lipid complexes
|
EP1104306B1
(en)
*
|
1998-08-10 |
2006-01-11 |
Antigenics Inc. |
Compositions of cpg and saponin adjuvants and methods of use thereof
|
PT1832657E
(pt)
*
|
1998-09-09 |
2013-01-08 |
Genzyme Corp |
Metilação de vectores plasmídicos
|
US20020065236A1
(en)
*
|
1998-09-09 |
2002-05-30 |
Yew Nelson S. |
CpG reduced plasmids and viral vectors
|
WO2000020039A1
(en)
*
|
1998-10-05 |
2000-04-13 |
The Regents Of The University Of California |
Methods and adjuvants for stimulating mucosal immunity
|
US6558951B1
(en)
*
|
1999-02-11 |
2003-05-06 |
3M Innovative Properties Company |
Maturation of dendritic cells with immune response modifying compounds
|
AU783344B2
(en)
|
1999-02-17 |
2005-10-20 |
Csl Limited |
Immunogenic complexes and methods relating thereto
|
ES2228454T3
(es)
|
1999-02-26 |
2005-04-16 |
Chiron S.R.L. |
Mejora de la actividad bacteriana de antigenos de neisseria con oligonucleotidos que contienen motivos cg.
|
WO2000050006A2
(en)
|
1999-02-26 |
2000-08-31 |
Chiron Corporation |
Microemulsions with adsorbed macromoelecules and microparticles
|
US6977245B2
(en)
|
1999-04-12 |
2005-12-20 |
The United States Of America As Represented By The Department Of Health And Human Services |
Oligodeoxynucleotide and its use to induce an immune response
|
EP1176966B1
(en)
|
1999-04-12 |
2013-04-03 |
THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES |
Oligodeoxynucleotide and its use to induce an immune response
|
US20040009936A1
(en)
*
|
1999-05-03 |
2004-01-15 |
Tang De-Chu C. |
Vaccine and drug delivery by topical application of vectors and vector extracts
|
US20050244434A1
(en)
*
|
1999-08-12 |
2005-11-03 |
Cohen David I |
Tat-based tolerogen compositions and methods of making and using same
|
US20050226890A1
(en)
*
|
1999-08-12 |
2005-10-13 |
Cohen David I |
Tat-based vaccine compositions and methods of making and using same
|
EP1204425B1
(en)
|
1999-08-19 |
2009-01-07 |
Dynavax Technologies Corporation |
Methods of modulating an immune response using immunostimulatory sequences and compositions for use therein
|
DK1221955T3
(da)
*
|
1999-09-25 |
2006-01-30 |
Univ Iowa Res Found |
Immunstimulerende nukleinsyre
|
US6949520B1
(en)
|
1999-09-27 |
2005-09-27 |
Coley Pharmaceutical Group, Inc. |
Methods related to immunostimulatory nucleic acid-induced interferon
|
EP1688147A1
(en)
*
|
1999-09-27 |
2006-08-09 |
Coley Pharmaceutical Group, Inc. |
Methods Related to Immunostimulatory Nucleic Acid-Induced Interferon
|
CA2386019C
(en)
*
|
1999-09-27 |
2011-06-21 |
Coley Pharmaceutical Group, Inc. |
Methods related to immunostimulatory nucleic acid-induced interferon
|
CA2390031A1
(en)
*
|
1999-11-02 |
2001-05-25 |
Chiron Corporation |
Double-stranded rna receptor (dsrna-r) and methods relating thereto
|
US20040234539A1
(en)
*
|
1999-11-03 |
2004-11-25 |
Powderject Research Limited |
Nucleic acid vaccine compositions having a mammalian cd80/cd86 gene promoter driving antigen expression
|
AU1358501A
(en)
*
|
1999-11-03 |
2001-05-14 |
Powderject Vaccines, Inc. |
Nucleic acid vaccine compositions having a mammalian cd80/cd86 gene promoter driving antigen expression
|
US7223398B1
(en)
|
1999-11-15 |
2007-05-29 |
Dynavax Technologies Corporation |
Immunomodulatory compositions containing an immunostimulatory sequence linked to antigen and methods of use thereof
|
CA2391843C
(en)
*
|
1999-11-19 |
2011-10-18 |
Csl Limited |
Hcv vaccine compositions
|
CA2291367A1
(en)
*
|
1999-12-06 |
2001-06-06 |
Isabelle Henry |
Genetic constructions having a reduced or an increased number of epigenetic control regions and methods of use thereof
|
ATE378348T1
(de)
*
|
2000-01-14 |
2007-11-15 |
Us Health |
Oligodeoxynukleotide und ihre verwendung zur induktion einer immunreaktion
|
US7585847B2
(en)
*
|
2000-02-03 |
2009-09-08 |
Coley Pharmaceutical Group, Inc. |
Immunostimulatory nucleic acids for the treatment of asthma and allergy
|
US20040131628A1
(en)
*
|
2000-03-08 |
2004-07-08 |
Bratzler Robert L. |
Nucleic acids for the treatment of disorders associated with microorganisms
|
US20020028784A1
(en)
*
|
2000-03-10 |
2002-03-07 |
Nest Gary Van |
Methods of preventing and treating viral infections using immunomodulatory polynucleotide sequences
|
US20020107212A1
(en)
*
|
2000-03-10 |
2002-08-08 |
Nest Gary Van |
Methods of reducing papillomavirus infection using immunomodulatory polynucleotide sequences
|
US20020098199A1
(en)
*
|
2000-03-10 |
2002-07-25 |
Gary Van Nest |
Methods of suppressing hepatitis virus infection using immunomodulatory polynucleotide sequences
|
US20030129251A1
(en)
|
2000-03-10 |
2003-07-10 |
Gary Van Nest |
Biodegradable immunomodulatory formulations and methods for use thereof
|
US20010046967A1
(en)
*
|
2000-03-10 |
2001-11-29 |
Gary Van Nest |
Methods of preventing and treating respiratory viral infection using immunomodulatory polynucleotide
|
US7157437B2
(en)
*
|
2000-03-10 |
2007-01-02 |
Dynavax Technologies Corporation |
Methods of ameliorating symptoms of herpes infection using immunomodulatory polynucleotide sequences
|
US7129222B2
(en)
|
2000-03-10 |
2006-10-31 |
Dynavax Technologies Corporation |
Immunomodulatory formulations and methods for use thereof
|
PT1296714E
(pt)
*
|
2000-06-22 |
2009-10-15 |
Coley Pharm Gmbh |
Combinação de cpg e anticorpos dirigidos contra cd19, cd20, cd22 ou cd40 para o tratamento ou prevenção do cancro
|
WO2002002172A1
(en)
*
|
2000-06-30 |
2002-01-10 |
Univ Jefferson |
Dna palindrome - oligoguanylic acid compositions and uses thereof
|
KR100917101B1
(ko)
*
|
2000-08-04 |
2009-09-15 |
도요 보세키 가부시키가이샤 |
플렉시블 금속적층체 및 그 제조방법
|
WO2006033665A1
(en)
*
|
2004-03-16 |
2006-03-30 |
Inist Inc. |
Tat-based vaccine compositions and methods of making and using same
|
JP2005500806A
(ja)
*
|
2000-09-15 |
2005-01-13 |
コーリー ファーマシューティカル ゲーエムベーハー |
CpGに基づく免疫アゴニスト/免疫アンタゴニストの高スループットスクリーニングのためのプロセス
|
US7939087B2
(en)
|
2000-10-27 |
2011-05-10 |
Novartis Vaccines And Diagnostics, Inc. |
Nucleic acids and proteins from Streptococcus groups A & B
|
TWI255272B
(en)
*
|
2000-12-06 |
2006-05-21 |
Guriq Basi |
Humanized antibodies that recognize beta amyloid peptide
|
US7700751B2
(en)
|
2000-12-06 |
2010-04-20 |
Janssen Alzheimer Immunotherapy |
Humanized antibodies that recognize β-amyloid peptide
|
US6677347B2
(en)
*
|
2000-12-08 |
2004-01-13 |
3M Innovative Properties Company |
Sulfonamido ether substituted imidazoquinolines
|
EP1850850A4
(en)
*
|
2000-12-08 |
2011-06-15 |
3M Innovative Properties Co |
COMPOSITIONS AND METHOD FOR TARGETED ADMINISTRATION OF IMMUNE RESPONSE MODIFICATORS
|
AU2001297693A1
(en)
|
2000-12-08 |
2002-09-12 |
Coley Pharmaceutical Gmbh |
Cpg-like nucleic acids and methods of use thereof
|
CN1293192C
(zh)
|
2000-12-27 |
2007-01-03 |
戴纳瓦克斯技术公司 |
免疫调节性多核苷酸及其使用方法
|
US20030050268A1
(en)
*
|
2001-03-29 |
2003-03-13 |
Krieg Arthur M. |
Immunostimulatory nucleic acid for treatment of non-allergic inflammatory diseases
|
EP1390494A2
(en)
|
2001-05-21 |
2004-02-25 |
Intercell AG |
Method for stabilising of nucleic acids
|
WO2002099105A2
(en)
*
|
2001-06-05 |
2002-12-12 |
Cellectis |
Methods for modifying the cpg content of polynucleotides
|
US6818787B2
(en)
*
|
2001-06-11 |
2004-11-16 |
Xenoport, Inc. |
Prodrugs of GABA analogs, compositions and uses thereof
|
GB0115176D0
(en)
|
2001-06-20 |
2001-08-15 |
Chiron Spa |
Capular polysaccharide solubilisation and combination vaccines
|
CN100334228C
(zh)
*
|
2001-06-21 |
2007-08-29 |
戴纳瓦克斯技术公司 |
嵌合免疫调制化合物及其使用方法
|
US7785610B2
(en)
*
|
2001-06-21 |
2010-08-31 |
Dynavax Technologies Corporation |
Chimeric immunomodulatory compounds and methods of using the same—III
|
GB0118249D0
(en)
|
2001-07-26 |
2001-09-19 |
Chiron Spa |
Histidine vaccines
|
US7666674B2
(en)
|
2001-07-27 |
2010-02-23 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Use of sterically stabilized cationic liposomes to efficiently deliver CPG oligonucleotides in vivo
|
GB0121591D0
(en)
|
2001-09-06 |
2001-10-24 |
Chiron Spa |
Hybrid and tandem expression of neisserial proteins
|
AU2002318944A1
(en)
*
|
2001-08-01 |
2003-02-17 |
Coley Pharmaceutical Gmbh |
Methods and compositions relating to plasmacytoid dendritic cells
|
JP4607452B2
(ja)
|
2001-08-07 |
2011-01-05 |
ダイナバックス テクノロジーズ コーポレイション |
免疫調節性組成物、製剤およびその使用方法
|
AU2001281267B2
(en)
*
|
2001-08-10 |
2008-05-15 |
Dynavax Technologies Corporation |
Immunomodulatory oligonnucleotide formulations and methods for use thereof
|
WO2003020884A2
(en)
*
|
2001-08-14 |
2003-03-13 |
The Government Of The United States Of America As Represented By The Secretary Of Health And Human Services |
Method for rapid generation of mature dendritic cells
|
DK1446162T3
(da)
|
2001-08-17 |
2008-12-08 |
Coley Pharm Gmbh |
Kombinationsmotiv-immunstimulatoriske oligonukleotider med forbedret aktivitet
|
ES2388170T3
(es)
|
2001-08-24 |
2012-10-09 |
Uvic Industry Partnerships Inc. |
Proaerolisina que contiene secuencias de activación de proteasa y métodos de uso para el tratamiento del cáncer de próstata
|
CA2458876A1
(en)
*
|
2001-08-30 |
2003-03-13 |
3M Innovative Properties Company |
Methods of maturing plasmacytoid dendritic cells using immune response modifier molecules
|
KR20040053122A
(ko)
*
|
2001-09-07 |
2004-06-23 |
더 트러스티즈 오브 보스톤 유니버시티 |
면역 복합체 관련 질환의 치료 방법 및 이를 위한 조성물
|
DE60234375D1
(de)
*
|
2001-09-14 |
2009-12-24 |
Cytos Biotechnology Ag |
VERPACKUNG VON IMMUNSTIMULIERENDEM CpG IN VIRUSÄHNLICHEN PARTIKELN: HERSTELLUNGSVERFAHREN UND VERWENDUNG
|
AU2002347404A1
(en)
*
|
2001-09-14 |
2003-04-01 |
Cytos Biotechnology Ag |
In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles
|
US7514414B2
(en)
|
2001-09-24 |
2009-04-07 |
The United States Of America As Represented By The Department Of Health And Human Services |
Suppressors of CpG oligonucleotides and methods of use
|
WO2004012669A2
(en)
|
2002-08-01 |
2004-02-12 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Method of treating inflammatory arthropathies with suppressors of cpg oligonucleotides
|
AR045702A1
(es)
|
2001-10-03 |
2005-11-09 |
Chiron Corp |
Composiciones de adyuvantes.
|
WO2003031573A2
(en)
*
|
2001-10-05 |
2003-04-17 |
Coley Pharmaceutical Gmbh |
Toll-like receptor 3 signaling agonists and antagonists
|
US20030139364A1
(en)
*
|
2001-10-12 |
2003-07-24 |
University Of Iowa Research Foundation |
Methods and products for enhancing immune responses using imidazoquinoline compounds
|
EP1441763A2
(en)
*
|
2001-11-07 |
2004-08-04 |
Inex Pharmaceuticals Corp. |
Mucosal adjuvants comprising an oligonucleotide and a cationic lipid
|
PT1719511E
(pt)
*
|
2001-11-16 |
2009-03-06 |
Coley Pharm Group Inc |
N-[4-(4-amino-2-etil-1h-imidazo[4,5-c]quinolina-1- -il)-butil]-metano-sulfonamida, uma composição farmacêutica que a contém e sua utilização
|
CA2435758C
(en)
|
2001-11-21 |
2016-08-02 |
The Board Of Trustees Of The Leland Stanford Junior University |
Polynucleotide therapy against autoantigens for treating insulin dependent diabetes mellitus
|
US8466116B2
(en)
|
2001-12-20 |
2013-06-18 |
The Unites States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Use of CpG oligodeoxynucleotides to induce epithelial cell growth
|
AU2002366710A1
(en)
|
2001-12-20 |
2003-07-09 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of |
USE OF CpG OLIGODEOXYNUCLEOTIDES TO INDUCE ANGIOGENESIS
|
CA2365732A1
(en)
*
|
2001-12-20 |
2003-06-20 |
Ibm Canada Limited-Ibm Canada Limitee |
Testing measurements
|
EP2572707A3
(en)
|
2002-02-20 |
2013-11-06 |
Novartis Vaccines and Diagnostics, Inc. |
Microparticles with adsorbed polypeptide-containing molecules
|
HUE025145T2
(en)
*
|
2002-02-22 |
2016-01-28 |
Meda Ab |
A method for reducing and treating immunosuppression induced by ultraviolet B radiation
|
MY139983A
(en)
*
|
2002-03-12 |
2009-11-30 |
Janssen Alzheimer Immunotherap |
Humanized antibodies that recognize beta amyloid peptide
|
US20050222060A1
(en)
*
|
2002-03-15 |
2005-10-06 |
Bot Adrian L |
Compositions and methods to initiate or enhance antibody and major-histocompatibility class I or class II-restricted t cell responses by using immunomodulatory, non-coding rna motifs
|
EP2258712A3
(en)
*
|
2002-03-15 |
2011-05-04 |
Multicell Immunotherapeutics, Inc. |
Compositions and Methods to Initiate or Enhance Antibody and Major-histocompatibility Class I or Class II-restricted T Cell Responses by Using Immunomodulatory, Non-coding RNA Motifs
|
AU2003230806B2
(en)
|
2002-04-04 |
2009-05-07 |
Zoetis Belgium S.A. |
Immunostimulatory G,U-containing oligoribonucleotides
|
US20030224013A1
(en)
*
|
2002-04-19 |
2003-12-04 |
Cole Garry T. |
Methods for protection against Coccidioides spp. infection using Coccidioides spp. urea amidohydrolase (Ure) protein
|
JP2006515266A
(ja)
*
|
2002-04-22 |
2006-05-25 |
バイオニケ ライフ サイエンシーズ インコーポレイテッド |
オリゴヌクレオチド組成物および免疫応答の調節のためのそれらの使用
|
US20040009944A1
(en)
*
|
2002-05-10 |
2004-01-15 |
Inex Pharmaceuticals Corporation |
Methylated immunostimulatory oligonucleotides and methods of using the same
|
KR100456681B1
(ko)
*
|
2002-05-22 |
2004-11-10 |
주식회사 대웅 |
박테리아의 염색체 dna 파쇄물과 비독성리포폴리사카라이드를 포함하는 면역강화 및 조절 조성물
|
CA2388049A1
(en)
*
|
2002-05-30 |
2003-11-30 |
Immunotech S.A. |
Immunostimulatory oligonucleotides and uses thereof
|
WO2003103586A2
(en)
*
|
2002-06-05 |
2003-12-18 |
Coley Pharmaceutical Group, Inc. |
Method for treating autoimmune or inflammatory diseases with combinations of inhibitory oligonucleotides and small molecule antagonists of immunostimulatory cpg nucleic acids
|
RU2322257C2
(ru)
*
|
2002-06-20 |
2008-04-20 |
Цитос Байотекнолоджи Аг |
КОМПОЗИЦИИ, СОДЕРЖАЩИЕ CpG-ОЛИГОНУКЛЕОТИДЫ И ВИРУСОПОДОБНЫЕ ЧАСТИЦЫ, ДЛЯ ПРИМЕНЕНИЯ В КАЧЕСТВЕ АДЪЮВАНТОВ
|
US7807803B2
(en)
*
|
2002-07-03 |
2010-10-05 |
Coley Pharmaceutical Group, Inc. |
Nucleic acid compositions for stimulating immune responses
|
US7576066B2
(en)
*
|
2002-07-03 |
2009-08-18 |
Coley Pharmaceutical Group, Inc. |
Nucleic acid compositions for stimulating immune responses
|
US20040053880A1
(en)
*
|
2002-07-03 |
2004-03-18 |
Coley Pharmaceutical Group, Inc. |
Nucleic acid compositions for stimulating immune responses
|
US7605138B2
(en)
*
|
2002-07-03 |
2009-10-20 |
Coley Pharmaceutical Group, Inc. |
Nucleic acid compositions for stimulating immune responses
|
US7569553B2
(en)
|
2002-07-03 |
2009-08-04 |
Coley Pharmaceutical Group, Inc. |
Nucleic acid compositions for stimulating immune responses
|
EP1523557A2
(en)
|
2002-07-24 |
2005-04-20 |
Intercell AG |
Antigens encoded by alternative reading frame from pathogenic viruses
|
NZ538812A
(en)
|
2002-08-15 |
2009-02-28 |
3M Innovative Properties Co |
Immunostimulatory compositions and methods of stimulating an immune response
|
AR040996A1
(es)
*
|
2002-08-19 |
2005-04-27 |
Coley Pharm Group Inc |
Acidos nucleicos inmunoestimuladores
|
GB0220194D0
(en)
|
2002-08-30 |
2002-10-09 |
Chiron Spa |
Improved vesicles
|
EP2402026A3
(en)
|
2002-09-13 |
2012-04-18 |
Intercell AG |
Method for isolating hepatitis C virus peptides
|
US8263091B2
(en)
*
|
2002-09-18 |
2012-09-11 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Method of treating and preventing infections in immunocompromised subjects with immunostimulatory CpG oligonucleotides
|
US7179797B2
(en)
*
|
2002-09-27 |
2007-02-20 |
Wisconsin Alumni Research Foundation |
Methods and compositions for treating prostate cancer using DNA vaccines
|
US8043622B2
(en)
|
2002-10-08 |
2011-10-25 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Method of treating inflammatory lung disease with suppressors of CpG oligonucleotides
|
WO2004037321A2
(en)
*
|
2002-10-25 |
2004-05-06 |
University Of Connecticut Health Center |
Immunotherapy of cancer through controlled cell lysis
|
US7998492B2
(en)
*
|
2002-10-29 |
2011-08-16 |
Coley Pharmaceutical Group, Inc. |
Methods and products related to treatment and prevention of hepatitis C virus infection
|
CA2504493C
(en)
*
|
2002-11-01 |
2015-12-29 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Method of preventing infections from bioterrorism agents with immunostimulatory cpg oligonucleotides
|
AU2003288660A1
(en)
|
2002-11-15 |
2004-06-15 |
Chiron Srl |
Unexpected surface proteins in neisseria meningitidis
|
GB0226717D0
(en)
*
|
2002-11-15 |
2002-12-24 |
Collen Res Foundation D |
DNA vaccination
|
US7811813B2
(en)
|
2002-11-21 |
2010-10-12 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods and immune modulatory nucleic acid compositions for preventing and treating disease
|
GB0227346D0
(en)
|
2002-11-22 |
2002-12-31 |
Chiron Spa |
741
|
JP2006512927A
(ja)
|
2002-12-11 |
2006-04-20 |
コーリー ファーマシューティカル グループ,インコーポレイテッド |
5’cpg核酸およびその使用方法
|
WO2004053057A2
(en)
*
|
2002-12-11 |
2004-06-24 |
3M Innovative Properties Company |
Gene expression systems and recombinant cell lines
|
AU2003287316A1
(en)
*
|
2002-12-11 |
2004-06-30 |
3M Innovative Properties Company |
Assays relating to toll-like receptor activity
|
AU2003300831A1
(en)
*
|
2002-12-11 |
2004-06-30 |
Hawaii Biotech, Inc. |
Recombinant vaccine against flavivirus infection
|
US8158768B2
(en)
|
2002-12-23 |
2012-04-17 |
Dynavax Technologies Corporation |
Immunostimulatory sequence oligonucleotides and methods of using the same
|
WO2004058179A2
(en)
|
2002-12-23 |
2004-07-15 |
Dynavax Technologies Corporation |
Immunostimulatory sequence oligonucleotides and methods of using the same
|
US8034378B2
(en)
|
2002-12-27 |
2011-10-11 |
Novartis Vaccines And Diagnostics, Inc |
Immunogenic compositions containing phospholipid
|
US7387271B2
(en)
|
2002-12-30 |
2008-06-17 |
3M Innovative Properties Company |
Immunostimulatory combinations
|
JP2006516639A
(ja)
*
|
2003-02-01 |
2006-07-06 |
ニユーララブ・リミテツド |
可溶性A−βに対する抗体を生成させるための能動免疫
|
EP1592302A4
(en)
*
|
2003-02-13 |
2007-04-25 |
3M Innovative Properties Co |
METHODS AND COMPOSITIONS ASSOCIATED WITH IMMUNE RESPONSE MODIFIER COMPOUNDS AND TOLL-LIKE RECEPTOR 8
|
AU2004213855B2
(en)
|
2003-02-20 |
2010-03-04 |
University Of Connecticut Health Center |
Methods and compositions for the treatment of cancer and infectious disease using alpha (2) macroglobulin-antigenic molecule complexes
|
US7485432B2
(en)
*
|
2003-02-27 |
2009-02-03 |
3M Innovative Properties Company |
Selective modulation of TLR-mediated biological activity
|
JP2006519866A
(ja)
|
2003-03-04 |
2006-08-31 |
スリーエム イノベイティブ プロパティズ カンパニー |
Uv誘発性の表皮の新形成の予防的治療
|
NZ567227A
(en)
*
|
2003-03-13 |
2010-01-29 |
3M Innovative Properties Co |
Methods of improving skin quality through topical application of an immune response modifier such as imiquimod
|
US7179253B2
(en)
|
2003-03-13 |
2007-02-20 |
3M Innovative Properties Company |
Method of tattoo removal
|
US7262027B2
(en)
*
|
2003-03-14 |
2007-08-28 |
Medical College Of Ohio |
Polypeptide and DNA immunization against Coccidioides spp. infections
|
WO2004084938A1
(en)
|
2003-03-24 |
2004-10-07 |
Intercell Ag |
Improved vaccines
|
US20040192585A1
(en)
*
|
2003-03-25 |
2004-09-30 |
3M Innovative Properties Company |
Treatment for basal cell carcinoma
|
US7517520B2
(en)
*
|
2003-03-26 |
2009-04-14 |
Cytos Biotechnology Ag |
Packaging of immunostimulatory oligonucleotides into virus-like particles: method of preparation and use
|
US7537767B2
(en)
|
2003-03-26 |
2009-05-26 |
Cytis Biotechnology Ag |
Melan-A- carrier conjugates
|
CN1795274A
(zh)
*
|
2003-03-26 |
2006-06-28 |
多单元免疫治疗公司 |
诱导细胞死亡和/或凋亡的选定的rna基序
|
AU2004226605A1
(en)
*
|
2003-04-02 |
2004-10-14 |
Coley Pharmaceutical Group, Ltd. |
Immunostimulatory nucleic acid oil-in-water formulations for topical application
|
JP2006522823A
(ja)
*
|
2003-04-10 |
2006-10-05 |
スリーエム イノベイティブ プロパティズ カンパニー |
免疫反応調節物質化合物の送達
|
US20040265351A1
(en)
*
|
2003-04-10 |
2004-12-30 |
Miller Richard L. |
Methods and compositions for enhancing immune response
|
SE0301109D0
(sv)
|
2003-04-14 |
2003-04-14 |
Mallen Huang |
Nucleotide vaccine composition
|
WO2004096144A2
(en)
*
|
2003-04-28 |
2004-11-11 |
3M Innovative Properties Company |
Compositions and methods for induction of opioid receptors
|
PE20050627A1
(es)
*
|
2003-05-30 |
2005-08-10 |
Wyeth Corp |
Anticuerpos humanizados que reconocen el peptido beta amiloideo
|
CN1798548B
(zh)
|
2003-06-02 |
2010-05-05 |
诺华疫苗和诊断公司 |
基于含吸附类毒素和含多糖抗原微粒体的免疫原性组合物
|
WO2005000884A1
(en)
|
2003-06-05 |
2005-01-06 |
The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services |
Poly-gamma-glutamic conjugates for eliciting immune responses directed against bacilli
|
MXPA05013922A
(es)
*
|
2003-06-20 |
2006-02-24 |
Coley Pharm Group Inc |
Antagonistas de receptor tipo toll de molecula pequena.
|
US20050013812A1
(en)
*
|
2003-07-14 |
2005-01-20 |
Dow Steven W. |
Vaccines using pattern recognition receptor-ligand:lipid complexes
|
AU2004261987A1
(en)
*
|
2003-07-31 |
2005-02-10 |
3M Innovative Properties Company |
Compositions for encapsulation and controlled release
|
US20050070460A1
(en)
*
|
2003-08-05 |
2005-03-31 |
3M Innovative Properties Company |
Infection prophylaxis using immune response modifier compounds
|
EP1653914A4
(en)
*
|
2003-08-12 |
2008-10-29 |
3M Innovative Properties Co |
COMPOUNDS CONTAINING OXIME SUBSTITUTED IMIDAZO STRUCTURE
|
US20060035242A1
(en)
|
2004-08-13 |
2006-02-16 |
Michelitsch Melissa D |
Prion-specific peptide reagents
|
KR100662660B1
(ko)
|
2003-08-13 |
2007-01-02 |
학교법인 한림대학교 |
사이토메가로바이러스 ie 인헨서/프로모터의 활성을촉진하는 올리고뉴크레오타이드
|
JP2007504145A
(ja)
*
|
2003-08-25 |
2007-03-01 |
スリーエム イノベイティブ プロパティズ カンパニー |
免疫刺激性の組み合わせおよび治療
|
AU2004268616B2
(en)
*
|
2003-08-25 |
2010-10-07 |
3M Innovative Properties Company |
Delivery of immune response modifier compounds
|
NZ545412A
(en)
*
|
2003-08-27 |
2008-12-24 |
Coley Pharm Group Inc |
Aryloxy and arylalkyleneoxy substituted imidazoquinolines
|
CA2536578A1
(en)
*
|
2003-09-02 |
2005-03-10 |
3M Innovative Properties Company |
Methods related to the treatment of mucosal associated conditions
|
CA2537763A1
(en)
*
|
2003-09-05 |
2005-03-17 |
3M Innovative Properties Company |
Treatment for cd5+ b cell lymphoma
|
CA2536139A1
(en)
*
|
2003-09-25 |
2005-04-07 |
Coley Pharmaceutical Group, Inc. |
Nucleic acid-lipophilic conjugates
|
US7544697B2
(en)
*
|
2003-10-03 |
2009-06-09 |
Coley Pharmaceutical Group, Inc. |
Pyrazolopyridines and analogs thereof
|
US20090075980A1
(en)
*
|
2003-10-03 |
2009-03-19 |
Coley Pharmaceutical Group, Inc. |
Pyrazolopyridines and Analogs Thereof
|
BRPI0414856A
(pt)
*
|
2003-10-03 |
2006-11-21 |
3M Innovative Properties Co |
imidazoquinolinas alcóxi-substituìdas
|
WO2005034979A2
(en)
*
|
2003-10-11 |
2005-04-21 |
Inex Pharmaceuticals Corporation |
Methods and compositions for enhancing innate immunity and antibody dependent cellular cytotoxicity
|
KR101107818B1
(ko)
*
|
2003-10-30 |
2012-01-31 |
콜레이 파마시티컬 그룹, 인코포레이티드 |
향상된 면역자극 효능을 가진 c-부류 올리고뉴클레오티드유사체
|
JP2007509987A
(ja)
*
|
2003-10-31 |
2007-04-19 |
スリーエム イノベイティブ プロパティズ カンパニー |
免疫応答調節剤化合物による好中球活性化
|
US20050239733A1
(en)
*
|
2003-10-31 |
2005-10-27 |
Coley Pharmaceutical Gmbh |
Sequence requirements for inhibitory oligonucleotides
|
US20050100983A1
(en)
*
|
2003-11-06 |
2005-05-12 |
Coley Pharmaceutical Gmbh |
Cell-free methods for identifying compounds that affect toll-like receptor 9 (TLR9) signaling
|
CA2545825A1
(en)
*
|
2003-11-14 |
2005-06-02 |
3M Innovative Properties Company |
Hydroxylamine substituted imidazo ring compounds
|
CN1906193A
(zh)
|
2003-11-14 |
2007-01-31 |
3M创新有限公司 |
肟取代的咪唑环化合物
|
MXPA06005910A
(es)
*
|
2003-11-25 |
2006-08-23 |
3M Innovative Properties Co |
Sistemas de anillo imidazo sustituido y metodos.
|
US20050287118A1
(en)
*
|
2003-11-26 |
2005-12-29 |
Epitomics, Inc. |
Bacterial plasmid with immunological adjuvant function and uses thereof
|
US20050277127A1
(en)
*
|
2003-11-26 |
2005-12-15 |
Epitomics, Inc. |
High-throughput method of DNA immunogen preparation and immunization
|
US8940755B2
(en)
*
|
2003-12-02 |
2015-01-27 |
3M Innovative Properties Company |
Therapeutic combinations and methods including IRM compounds
|
US20050226878A1
(en)
*
|
2003-12-02 |
2005-10-13 |
3M Innovative Properties Company |
Therapeutic combinations and methods including IRM compounds
|
JP4817599B2
(ja)
*
|
2003-12-25 |
2011-11-16 |
独立行政法人科学技術振興機構 |
免疫活性増強剤とこれを用いた免疫活性の増強方法
|
WO2005066170A1
(en)
*
|
2003-12-29 |
2005-07-21 |
3M Innovative Properties Company |
Arylalkenyl and arylalkynyl substituted imidazoquinolines
|
WO2005067500A2
(en)
*
|
2003-12-30 |
2005-07-28 |
3M Innovative Properties Company |
Enhancement of immune responses
|
JP2007517044A
(ja)
*
|
2003-12-30 |
2007-06-28 |
スリーエム イノベイティブ プロパティズ カンパニー |
イミダゾキノリニル、イミダゾピリジニル、およびイミダゾナフチリジニルスルホンアミド
|
GB0401876D0
(en)
|
2004-01-28 |
2004-03-03 |
Vereniging Het Nl Kanker I |
New use for cancer antigen
|
US20050181035A1
(en)
*
|
2004-02-17 |
2005-08-18 |
Dow Steven W. |
Systemic immune activation method using non CpG nucleic acids
|
TW200533750A
(en)
*
|
2004-02-19 |
2005-10-16 |
Coley Pharm Group Inc |
Immunostimulatory viral RNA oligonucleotides
|
AU2005216075B2
(en)
*
|
2004-02-20 |
2011-03-10 |
Idera Pharmaceuticals, Inc. |
Potent mucosal immune response induced by modified immunomodulatory oligonucleotides
|
AU2005228150A1
(en)
*
|
2004-03-24 |
2005-10-13 |
3M Innovative Properties Company |
Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
|
TWI235440B
(en)
*
|
2004-03-31 |
2005-07-01 |
Advanced Semiconductor Eng |
Method for making leadless semiconductor package
|
US20060051374A1
(en)
*
|
2004-04-28 |
2006-03-09 |
3M Innovative Properties Company |
Compositions and methods for mucosal vaccination
|
DE602005012948D1
(de)
|
2004-05-06 |
2009-04-09 |
Us Gov Health & Human Serv |
Verfahren und zusammensetzungen zur behandlung von uveitis
|
US20050267145A1
(en)
*
|
2004-05-28 |
2005-12-01 |
Merrill Bryon A |
Treatment for lung cancer
|
ES2560449T3
(es)
|
2004-05-28 |
2016-02-19 |
Oryxe |
Una mezcla para administración transdérmica de compuestos de peso molecular bajo y alto
|
US8017779B2
(en)
*
|
2004-06-15 |
2011-09-13 |
3M Innovative Properties Company |
Nitrogen containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines
|
WO2006009832A1
(en)
*
|
2004-06-18 |
2006-01-26 |
3M Innovative Properties Company |
Substituted imidazo ring systems and methods
|
US8026366B2
(en)
*
|
2004-06-18 |
2011-09-27 |
3M Innovative Properties Company |
Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines
|
WO2006065280A2
(en)
*
|
2004-06-18 |
2006-06-22 |
3M Innovative Properties Company |
Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and methods
|
US7897609B2
(en)
*
|
2004-06-18 |
2011-03-01 |
3M Innovative Properties Company |
Aryl substituted imidazonaphthyridines
|
CA2572427A1
(en)
|
2004-07-18 |
2006-01-18 |
Heather L. Davis |
Immuno stimulating complex and oligonucleotide formulations for inducing enhanced interferon-gamma responses
|
JP4550115B2
(ja)
*
|
2004-08-03 |
2010-09-22 |
ジーンアート・アクチエンゲゼルシャフト |
CpG含量を変化させることにより遺伝子発現を調整する方法
|
US20060045886A1
(en)
*
|
2004-08-27 |
2006-03-02 |
Kedl Ross M |
HIV immunostimulatory compositions
|
WO2006026760A2
(en)
*
|
2004-09-02 |
2006-03-09 |
3M Innovative Properties Company |
1-amino imidazo-containing compounds and methods
|
EP1791858B1
(en)
|
2004-09-24 |
2010-04-21 |
Intercell AG |
Modified vp1-capsid protein of parvovirus b19
|
EP1804583A4
(en)
*
|
2004-10-08 |
2009-05-20 |
3M Innovative Properties Co |
ADJUVANT FOR DNA VACCINE
|
EP3312272B1
(en)
|
2004-10-08 |
2019-08-28 |
The Government of The United States of America as represented by The Secretary of The Department of Health and Human Services |
Modulation of replicative fitness by using less frequently used synonymous codons
|
EP1811026B1
(en)
*
|
2004-10-15 |
2015-01-28 |
Sekisui Chemical Co., Ltd. |
Method of immunizing animal, composition for immunization, method of producing antibody, method of producing hybridoma and method of producing monoclonal antibody
|
MY159370A
(en)
*
|
2004-10-20 |
2016-12-30 |
Coley Pharm Group Inc |
Semi-soft-class immunostimulatory oligonucleotides
|
US7332324B2
(en)
|
2004-12-03 |
2008-02-19 |
University Of Toledo |
Attenuated vaccine useful for immunizations against Coccidioides spp. infections
|
WO2006063072A2
(en)
*
|
2004-12-08 |
2006-06-15 |
3M Innovative Properties Company |
Immunomodulatory compositions, combinations and methods
|
US9809824B2
(en)
|
2004-12-13 |
2017-11-07 |
The United States Of America, Represented By The Secretary, Department Of Health And Human Services |
CpG oligonucleotide prodrugs, compositions thereof and associated therapeutic methods
|
JP2008523815A
(ja)
*
|
2004-12-15 |
2008-07-10 |
エラン ファーマ インターナショナル リミテッド |
認知の改善における使用のためのヒト化アミロイドβ抗体
|
WO2006071997A2
(en)
|
2004-12-30 |
2006-07-06 |
3M Innovative Properties Company |
Treatment for cutaneous metastases
|
EP1831226B1
(en)
*
|
2004-12-30 |
2012-08-08 |
3M Innovative Properties Company |
Chiral tetracyclic compounds inducing interferon biosynthesis
|
JP5313502B2
(ja)
|
2004-12-30 |
2013-10-09 |
スリーエム イノベイティブ プロパティズ カンパニー |
置換キラル縮合[1,2]イミダゾ[4,5−c]環状化合物
|
JP4993750B2
(ja)
|
2005-01-27 |
2012-08-08 |
チルドレンズ ホスピタル アンド リサーチ センター アット オークランド |
髄膜炎菌に起因する疾患に対する広域防御のための、gna1870を基にした小胞ワクチン
|
US9248127B2
(en)
*
|
2005-02-04 |
2016-02-02 |
3M Innovative Properties Company |
Aqueous gel formulations containing immune response modifiers
|
CA2597587A1
(en)
|
2005-02-11 |
2006-08-17 |
Coley Pharmaceutical Group, Inc. |
Oxime and hydroxylamine substituted imidazo[4,5-c] ring compounds and methods
|
US20080009455A9
(en)
*
|
2005-02-24 |
2008-01-10 |
Coley Pharmaceutical Group, Inc. |
Immunostimulatory oligonucleotides
|
JP2008538550A
(ja)
|
2005-04-01 |
2008-10-30 |
コーリー ファーマシューティカル グループ,インコーポレイテッド |
ウイルス感染および腫瘍性疾患を処置するためのサイトカイン生合成の調節因子としての1−置換ピラゾロ(3,4−c)環状化合物
|
AU2006232377A1
(en)
|
2005-04-01 |
2006-10-12 |
Coley Pharmaceutical Group, Inc. |
Pyrazolopyridine-1,4-diamines and analogs thereof
|
JP2008535862A
(ja)
|
2005-04-08 |
2008-09-04 |
キメリクス,インコーポレイテッド |
ポックスウイルス感染の治療のための化合物、組成物および方法
|
AU2006235284A1
(en)
*
|
2005-04-08 |
2006-10-19 |
Coley Pharmaceutical Group, Inc. |
Methods for treating infectious disease exacerbated asthma
|
CA2605808A1
(en)
*
|
2005-04-25 |
2006-11-02 |
3M Innovative Properties Company |
Immunostimulatory compositions
|
US20060241076A1
(en)
*
|
2005-04-26 |
2006-10-26 |
Coley Pharmaceutical Gmbh |
Modified oligoribonucleotide analogs with enhanced immunostimulatory activity
|
ATE502954T1
(de)
|
2005-06-14 |
2011-04-15 |
Protox Therapeutics Inc |
Verfahren zur behandlung oder prävention gutartiger prostatahyperplasie unter verwendung modifizierter porenbildender proteine
|
PT2179737E
(pt)
|
2005-07-01 |
2013-12-05 |
Index Pharmaceuticals Ab |
Método para modular a capacidade de resposta aos esteróides
|
SI2269622T1
(sl)
*
|
2005-07-01 |
2014-05-30 |
Index Pharmaceuticals Ab |
CpG OLIGONUKLEOTIDI, KI SE UPORABLJAJO ZA IZBOLJĹ ANJE STEROIDNE AKTIVNOSTI PRI STEROIDNO ODVISNIH BOLNIKIH
|
NZ565311A
(en)
*
|
2005-07-07 |
2009-10-30 |
Pfizer |
Anti-ctla-4 antibody and cpg-motif-containing synthetic oligodeoxynucleotide combination therapy for cancer treatment
|
US20080206276A1
(en)
*
|
2005-07-08 |
2008-08-28 |
Michael Otto |
Targeting Poly-Gamma-Glutamic Acid to Treat Staphylococcus Epidermidis and Related Infections
|
EP1924692A2
(en)
*
|
2005-09-16 |
2008-05-28 |
Coley Pharmaceutical GmbH |
Modulation of immunostimulatory properties of short interfering ribonucleic acid (sirna) by nucleotide modification
|
EP1945766A2
(en)
*
|
2005-09-16 |
2008-07-23 |
Coley Pharmaceutical GmbH |
Immunostimulatory single-stranded ribonucleic acid with phosphodiester backbone
|
US20070081972A1
(en)
*
|
2005-09-30 |
2007-04-12 |
The University Of Iowa Research Foundation |
Polymer-based delivery system for immunotherapy of cancer
|
CA2625969A1
(en)
*
|
2005-10-28 |
2007-05-03 |
Index Pharmaceuticals Ab |
Composition and method for the prevention, treatment and/or alleviation of an inflammatory disease
|
KR20080072934A
(ko)
*
|
2005-11-25 |
2008-08-07 |
콜리 파마슈티칼 게엠베하 |
면역자극성 올리고리보뉴클레오티드
|
NZ569741A
(en)
|
2005-12-14 |
2012-02-24 |
Cytos Biotechnology Ag |
Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity
|
JP5473336B2
(ja)
*
|
2006-02-15 |
2014-04-16 |
アディウタイド・ファーマスーティカルズ・ゲーエムベーハー |
オリゴヌクレオチドの処方に関する組成物および方法
|
EP1988896A4
(en)
|
2006-02-22 |
2011-07-27 |
3M Innovative Properties Co |
CONJUGATES TO MODIFY IMMUNE REACTIONS
|
BRPI0708865A8
(pt)
|
2006-03-14 |
2019-01-22 |
Univ Oregon Health & Science |
métodos para produzir uma resposta imune à tuberculose
|
US8784810B2
(en)
*
|
2006-04-18 |
2014-07-22 |
Janssen Alzheimer Immunotherapy |
Treatment of amyloidogenic diseases
|
WO2007143582A2
(en)
*
|
2006-06-05 |
2007-12-13 |
Baylor College Of Medicine |
Reversal of the suppressive function of specific t cells via toll-like receptor 8 signaling
|
SI2032592T1
(sl)
|
2006-06-12 |
2013-10-30 |
Cytos Biotechnology Ag |
Postopki za pakiranje oligonukleotidov v virusu-podobne delce RNA bakteriofagov
|
WO2007147007A2
(en)
*
|
2006-06-13 |
2007-12-21 |
Bayhill Therapeutics, Inc. |
Methods and immune modulatory nucleic acid compositions for preventing and treating disease
|
WO2008094183A2
(en)
*
|
2006-07-11 |
2008-08-07 |
University Of Connecticut |
Use of conditional plasmodium strains lacking nutrient transporters in malaria vaccination
|
US8153116B2
(en)
|
2006-07-11 |
2012-04-10 |
University Of Connecticut |
Use of conditional plasmodium strains lacking an essential gene in malaria vaccination
|
US7906506B2
(en)
*
|
2006-07-12 |
2011-03-15 |
3M Innovative Properties Company |
Substituted chiral fused [1,2] imidazo [4,5-c] ring compounds and methods
|
WO2008027414A2
(en)
*
|
2006-08-29 |
2008-03-06 |
The United States Of America As Represented By The Secretary Of The Army, Walter Reed Army Institute Of Research |
Novel p. falciparum vaccine proteins and coding sequences
|
MX2009003398A
(es)
|
2006-09-27 |
2009-08-12 |
Coley Pharm Gmbh |
Analogos de oligonucleotidos cpg que contienen analogos t hidrofobos con actividad inmunoestimuladora mejorada.
|
KR20090058584A
(ko)
*
|
2006-10-26 |
2009-06-09 |
콜리 파마슈티칼 게엠베하 |
올리고리보뉴클레오티드 및 그의 용도
|
ES2465465T3
(es)
|
2006-11-01 |
2014-06-05 |
Ventana Medical Systems, Inc. |
Haptenos, conjugados de haptenos, composiciones de los mismos y método para su preparación y uso
|
US20090142362A1
(en)
*
|
2006-11-06 |
2009-06-04 |
Avant Immunotherapeutics, Inc. |
Peptide-based vaccine compositions to endogenous cholesteryl ester transfer protein (CETP)
|
US20080149123A1
(en)
|
2006-12-22 |
2008-06-26 |
Mckay William D |
Particulate material dispensing hairbrush with combination bristles
|
EP2125868B1
(en)
|
2007-02-28 |
2015-06-10 |
The Govt. Of U.S.A. As Represented By The Secretary Of The Department Of Health And Human Services |
Brachyury polypeptides and methods for use
|
US8003097B2
(en)
*
|
2007-04-18 |
2011-08-23 |
Janssen Alzheimer Immunotherapy |
Treatment of cerebral amyloid angiopathy
|
JP2011526240A
(ja)
*
|
2007-04-18 |
2011-10-06 |
ヤンセン アルツハイマー イミュノセラピー |
脳アミロイド血管症の予防および治療
|
US8518903B2
(en)
|
2007-04-19 |
2013-08-27 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Use of toll-like receptor-9 agonists
|
CN101678098A
(zh)
|
2007-05-17 |
2010-03-24 |
科勒制药集团公司 |
具有免疫刺激效力的a类寡核苷酸
|
EP2170353B1
(en)
*
|
2007-05-18 |
2015-06-03 |
AdiuTide Pharmaceuticals GmbH |
Phosphate-modified oligonucleotide analogs with immunostimulatory activity
|
CA2687178C
(en)
|
2007-05-23 |
2014-02-04 |
Ventana Medical Systems, Inc. |
Polymeric carriers for immunohistochemistry and in situ hybridization
|
EP2182983B1
(en)
|
2007-07-27 |
2014-05-21 |
Janssen Alzheimer Immunotherapy |
Treatment of amyloidogenic diseases with humanised anti-abeta antibodies
|
US7879812B2
(en)
|
2007-08-06 |
2011-02-01 |
University Of Iowa Research Foundation |
Immunomodulatory oligonucleotides and methods of use therefor
|
EP2185160B1
(en)
*
|
2007-08-31 |
2019-02-13 |
Neurimmune Holding AG |
Method of providing patient specific immune response in amyloidoses and protein aggregation disorders
|
CN101820908A
(zh)
|
2007-10-09 |
2010-09-01 |
科利制药公司 |
包含改性糖部分的免疫刺激寡核苷酸类似物
|
JO3076B1
(ar)
*
|
2007-10-17 |
2017-03-15 |
Janssen Alzheimer Immunotherap |
نظم العلاج المناعي المعتمد على حالة apoe
|
US8415361B2
(en)
|
2007-11-09 |
2013-04-09 |
The Salk Institute For Biological Studies |
Use of TAM receptor inhibitors as antimicrobials
|
US8815253B2
(en)
|
2007-12-07 |
2014-08-26 |
Novartis Ag |
Compositions for inducing immune responses
|
US20100040576A1
(en)
*
|
2007-12-18 |
2010-02-18 |
The Texas A&M University System |
Modified Oligonucleotides For The Treatment Of Hepatitis C Infection
|
EP2075003B1
(en)
*
|
2007-12-28 |
2010-09-01 |
Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts |
Parvovirus having a CpG-enriched genome useful for cancer therapy
|
WO2009105641A2
(en)
*
|
2008-02-20 |
2009-08-27 |
New York University |
Preventing and treating amyloid-beta deposition by stimulation of innate immunity
|
ES2557282T3
(es)
|
2008-03-10 |
2016-01-25 |
Children's Hospital & Research Center At Oakland |
Proteínas quiméricas de unión al factor H (fHBP) que contienen un dominio B heterólogo, y métodos de uso
|
US8222225B2
(en)
|
2008-05-21 |
2012-07-17 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Method of treating pneumoconiosis with oligodeoxynucleotides
|
CA2979353C
(en)
|
2008-06-05 |
2020-06-30 |
Ventana Medical Systems, Inc. |
Compositions comprising nanomaterials and method for using such compositions for histochemical processes
|
TWI351288B
(en)
*
|
2008-07-04 |
2011-11-01 |
Univ Nat Pingtung Sci & Tech |
Cpg dna adjuvant in avian vaccines
|
WO2010018583A1
(en)
*
|
2008-08-14 |
2010-02-18 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. |
Toll-like receptor 9 agonists for the treatment of anxiety-related disorders and inflammatory disorders
|
EP2385371B1
(en)
|
2008-09-22 |
2014-10-22 |
Oregon Health and Science University |
Methods for detecting a mycobacterium tuberculosis infection
|
NZ601345A
(en)
|
2008-10-16 |
2014-05-30 |
Univ Dalhousie |
Combination adjuvant formulation
|
US9067981B1
(en)
|
2008-10-30 |
2015-06-30 |
Janssen Sciences Ireland Uc |
Hybrid amyloid-beta antibodies
|
BRPI0923341B8
(pt)
|
2008-12-09 |
2021-05-25 |
Coley Pharm Group Inc |
oligonucleotideo imunoestimulador, vacina compreendendo o mesmo e seu uso
|
KR101644221B1
(ko)
|
2008-12-09 |
2016-07-29 |
화이자 백신스 엘엘씨 |
IgE CH3 펩티드 백신
|
US8552165B2
(en)
*
|
2008-12-09 |
2013-10-08 |
Heather Davis |
Immunostimulatory oligonucleotides
|
WO2010099472A2
(en)
|
2009-02-27 |
2010-09-02 |
The U.S.A. Of America, As Represented By The Secretary, Department Of Health And Human Services |
Spanx-b polypeptides and their use
|
CA2755897C
(en)
|
2009-03-23 |
2020-01-28 |
Nanirx, Inc. |
Treatment of cancers with immunostimulatory hiv tat derivative polypeptides
|
CA3033133C
(en)
|
2009-03-25 |
2021-11-09 |
The Board Of Regents Of The University Of Texas System |
Compositions for stimulation of mammalian innate immune resistance to pathogens
|
WO2010125480A1
(en)
|
2009-04-30 |
2010-11-04 |
Coley Pharmaceutical Group, Inc. |
Pneumococcal vaccine and uses thereof
|
MX2011012597A
(es)
|
2009-05-27 |
2012-04-19 |
Selecta Biosciences Inc |
Nanoportadores que poseen componentes con diferentes tasas de liberacion.
|
RU2518291C2
(ru)
|
2009-07-30 |
2014-06-10 |
Пфайзер Вэксинс ЭлЭлСи |
Антигенные tau-пептиды и их применения
|
US20110033515A1
(en)
*
|
2009-08-04 |
2011-02-10 |
Rst Implanted Cell Technology |
Tissue contacting material
|
WO2011026111A1
(en)
|
2009-08-31 |
2011-03-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Oral delivery of a vaccine to the large intestine to induce mucosal immunity
|
MY163512A
(en)
|
2009-09-03 |
2017-09-15 |
Pfizer Vaccines Llc |
Pcsk9 vaccine
|
US20110052666A1
(en)
*
|
2009-09-03 |
2011-03-03 |
Medtronic, Inc. |
Compositions, Methods, and Systems for SIRNA Delivery
|
WO2011041886A1
(en)
|
2009-10-07 |
2011-04-14 |
University Of Victoria Innovation And Development Corporation |
Vaccines comprising heat-sensitive transgenes
|
WO2011047340A1
(en)
|
2009-10-16 |
2011-04-21 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Insertion of foreign genes in rubella virus and their stable expression in a live, attenuated viral vaccine
|
US8961989B2
(en)
|
2009-11-20 |
2015-02-24 |
Oregon Health & Science University |
Methods for producing an immune response to tuberculosis
|
RU2581020C2
(ru)
|
2009-12-22 |
2016-04-10 |
Селлдекс Терапьютикс, Инк. |
Композиции вакцин
|
PT2534150T
(pt)
|
2010-02-12 |
2017-05-02 |
Chimerix Inc |
Métodos para tratar uma infecção viral
|
WO2011112599A2
(en)
|
2010-03-12 |
2011-09-15 |
The United States Of America, As Represented By The Secretary. Department Of Health & Human Services |
Immunogenic pote peptides and methods of use
|
WO2011126863A1
(en)
|
2010-03-30 |
2011-10-13 |
Children's Hospital & Research Center Oakland |
Factor h binding proteins (fhbp) with altered properties and methods of use thereof
|
LT2569436T
(lt)
|
2010-05-14 |
2018-03-12 |
Oregon Health & Science University |
Rekombinantiniai žcmv ir hcmv vektoriai ir jų panaudojimas
|
CN107080839A
(zh)
|
2010-05-26 |
2017-08-22 |
西莱克塔生物科技公司 |
多价的合成纳米载体疫苗
|
WO2011154878A1
(en)
|
2010-06-07 |
2011-12-15 |
Pfizer Vaccines Llc |
Ige ch3 peptide vaccine
|
CA2798837A1
(en)
|
2010-06-07 |
2011-12-15 |
Pfizer Inc. |
Her-2 peptides and vaccines
|
WO2012036993A1
(en)
|
2010-09-14 |
2012-03-22 |
University Of Pittsburgh-Of The Commonwealth System Of Higher Education |
Computationally optimized broadly reactive antigens for influenza
|
US10668092B2
(en)
|
2010-09-24 |
2020-06-02 |
The John Hopkins University |
Compositions and methods for treatment of inflammatory disorders
|
US9072760B2
(en)
|
2010-09-24 |
2015-07-07 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
TLR4 inhibitors for the treatment of human infectious and inflammatory disorders
|
EP2640190A4
(en)
|
2010-11-05 |
2016-05-11 |
Selecta Biosciences Inc |
MODIFIED NICOTINIC COMPOUNDS AND ASSOCIATED METHODS
|
WO2012088425A2
(en)
|
2010-12-22 |
2012-06-28 |
University Of Pittsburgh - Of The Commonwealth System Of Higher Education |
Gap junction-enhancing agents for treatment of necrotizing enterocolitis and inflammatory bowel disease
|
US20140004142A1
(en)
|
2011-03-02 |
2014-01-02 |
Pfizer Inc. |
Pcsk9 vaccine
|
JP5930146B2
(ja)
*
|
2011-03-28 |
2016-06-08 |
国立研究開発法人物質・材料研究機構 |
免疫刺激オリゴヌクレオチドおよび前記免疫刺激オリゴヌクレオチドを含む治療剤
|
EP2713737B1
(en)
|
2011-06-01 |
2016-04-20 |
Janus Biotherapeutics, Inc. |
Novel immune system modulators
|
JP6093759B2
(ja)
|
2011-06-01 |
2017-03-08 |
ジャナス バイオセラピューティクス,インク. |
新規の免疫系調節剤
|
BR112013031039B1
(pt)
|
2011-06-03 |
2020-04-28 |
3M Innovative Properties Co |
compostos de hidrazino 1h-imidazoquinolina-4-aminas, conjugados feitos destes compostos, composição e composição farmacêutica compreendendo ditos compostos e conjugados, usos dos mesmos e método de fabricação do conjugado
|
CA2838158C
(en)
|
2011-06-03 |
2019-07-16 |
3M Innovative Properties Company |
Heterobifunctional linkers with polyethylene glycol segments and immune response modifier conjugates made therefrom
|
AU2012273039B2
(en)
|
2011-06-20 |
2016-12-01 |
University Of Pittsburgh - Of The Commonwealth System Of Higher Education |
Computationally optimized broadly reactive antigens for H1N1 influenza
|
US20130023736A1
(en)
|
2011-07-21 |
2013-01-24 |
Stanley Dale Harpstead |
Systems for drug delivery and monitoring
|
CN103702687A
(zh)
|
2011-07-29 |
2014-04-02 |
西莱克塔生物科技公司 |
产生体液和细胞毒性t淋巴细胞(ctl)免疫应答的合成纳米载体
|
US20140348865A1
(en)
|
2011-09-12 |
2014-11-27 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Ser. |
Immunogens based on an hiv-1 v1v2 site-of-vulnerability
|
US20140234360A1
(en)
|
2011-09-30 |
2014-08-21 |
The United States of America, as represented by the Secretary, Dept.of Health and Human Services |
Influenza vaccine
|
IN2014KN00948A
(xx)
|
2011-10-04 |
2015-08-21 |
Janus Biotherapeutics Inc |
|
EP3269728B1
(en)
|
2011-10-20 |
2020-12-16 |
The Government of The United States of America as represented by The Secretary, Department of Health and Human Services |
Dengue virus e-glycoprotein polypeptides containing mutations that eliminate immunodominant cross-reactive epitopes
|
EP2596806A1
(en)
|
2011-11-25 |
2013-05-29 |
Index Pharmaceuticals AB |
Method for prevention of colectomy
|
FI123955B
(en)
*
|
2011-11-25 |
2014-01-15 |
Oncos Therapeutics Ltd |
Oncolytic adenovirus
|
SG10202013014RA
(en)
|
2012-01-16 |
2021-02-25 |
Mckenna Elizabeth |
Compositions and Methods for the Treatment of Hepatic Diseases and Disorders
|
CA2863981A1
(en)
|
2012-02-07 |
2013-08-15 |
University Of Pittsburgh - Of The Commonwealth System Of Higher Education |
Computationally optimized broadly reactive antigens for h3n2, h2n2, and b influenza viruses
|
US9566327B2
(en)
|
2012-02-13 |
2017-02-14 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Computationally optimized broadly reactive antigens for human and avian H5N1 influenza
|
CA2866185C
(en)
|
2012-03-23 |
2021-04-06 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Pathogenic phlebovirus isolates and compositions and methods of use
|
PE20142406A1
(es)
|
2012-05-04 |
2015-01-23 |
Pfizer |
Antigenos asociados a prostata y regimenes de inmunoterapia basados en vacuna
|
IN2014DN09618A
(xx)
|
2012-05-23 |
2015-07-31 |
Us Sec Dep Of Health And Human Services |
|
WO2013177397A1
(en)
|
2012-05-24 |
2013-11-28 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Multivalent meningococcal conjugates and methods for preparing cojugates
|
WO2013192144A2
(en)
|
2012-06-19 |
2013-12-27 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Rift valley fever virus replicon particles and use thereof
|
WO2014043518A1
(en)
|
2012-09-14 |
2014-03-20 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Brachyury protein, non-poxvirus non-yeast vectors encoding brachyury protein, and their use
|
CA2884918C
(en)
|
2012-09-17 |
2019-01-08 |
Novartis Tiergesundheit Ag |
Salmonid alphavirus and uses thereof
|
EP2898073A4
(en)
|
2012-09-21 |
2016-03-23 |
Elizabeth Mckenna |
Naturally-occurring CPG-oligonucleotide compositions and therapeutic applications thereof
|
WO2014052453A1
(en)
*
|
2012-09-25 |
2014-04-03 |
University Of Pittsburgh - Of The Commonwealth System Of Higher Education |
Oral therapy of necrotizing enterocolitis
|
EP2986717A1
(en)
|
2013-04-19 |
2016-02-24 |
The Regents of The University of California |
Lone star virus
|
US20210145963A9
(en)
|
2013-05-15 |
2021-05-20 |
The Governors Of The University Of Alberta |
E1e2 hcv vaccines and methods of use
|
EP3632458A1
(en)
|
2013-07-26 |
2020-04-08 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of bacterial infections
|
ES2957209T3
(es)
|
2013-09-30 |
2024-01-15 |
Triad Nat Security Llc |
Polipéptidos inmunogénicos mosaicos del VIH de región conservada
|
US9663556B2
(en)
|
2013-10-04 |
2017-05-30 |
Pin Pharma, Inc. |
Treatment of cancers with immunostimulatory HIV tat derivative polypeptides
|
KR102196884B1
(ko)
|
2013-11-01 |
2020-12-30 |
화이자 인코포레이티드 |
전립선-연관 항원의 발현을 위한 벡터
|
US10688129B2
(en)
|
2013-11-26 |
2020-06-23 |
Central Biomedia, Inc. |
Method of producing a designer blood product, method of using a designer blood product, and diet for selectively enhancing blood profile
|
JP6758185B2
(ja)
|
2013-12-13 |
2020-09-23 |
ザ ユナイテッド ステイツ オブ アメリカ, アズ リプレゼンテッド バイ ザ セクレタリー, デパートメント オブ ヘルス アンド ヒューマン サービシーズ |
マルチエピトープtarpペプチドワクチンおよびその使用
|
HUE055553T2
(hu)
|
2014-01-21 |
2021-12-28 |
Pfizer |
Streptococcus pneumoniae kapszulás poliszacharidok és azok konjugátumai
|
IL296681B2
(en)
|
2014-01-21 |
2024-09-01 |
Pfizer |
Immunogenic preparations including conjugated capsular saccharide antigens and their uses
|
US11160855B2
(en)
|
2014-01-21 |
2021-11-02 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
EP3957321A3
(en)
|
2014-01-21 |
2022-07-13 |
Pfizer Inc. |
Streptococcus pneumoniae capsular polysaccharides and conjugates thereof
|
WO2015123291A1
(en)
|
2014-02-11 |
2015-08-20 |
The Usa, As Represented By The Secretary, Dept. Of Health And Human Services |
Pcsk9 vaccine and methods of using the same
|
EP3149479A2
(en)
|
2014-05-30 |
2017-04-05 |
Sanofi Pasteur Inc. |
Expression and conformational analysis of engineered influenza hemagglutinin
|
EP3508198A1
(en)
|
2014-06-04 |
2019-07-10 |
Exicure, Inc. |
Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
|
CA3212723A1
(en)
|
2014-07-23 |
2016-01-28 |
Peter T. Beernink |
Factor h binding protein variants and methods of use thereof
|
US20170275287A1
(en)
|
2014-08-22 |
2017-09-28 |
Janus Biotherapeutics, Inc. |
Novel n2, n4, n7, 6-tetrasubstituted pteridine-2,4,7-triamine and 2, 4, 6, 7-tetrasubstituted pteridine compounds and methods of synthesis and use thereof
|
WO2016044839A2
(en)
|
2014-09-19 |
2016-03-24 |
The Board Of Regents Of The University Of Texas System |
Compositions and methods for treating viral infections through stimulated innate immunity in combination with antiviral compounds
|
CN107427568B
(zh)
|
2015-01-15 |
2021-12-14 |
辉瑞公司 |
用于肺炎球菌疫苗中的免疫原性组合物
|
CA3014427A1
(en)
|
2015-02-13 |
2016-08-18 |
Icahn School Of Medicine At Mount Sinai |
Rna containing compositions and methods of their use
|
WO2016180852A1
(en)
|
2015-05-12 |
2016-11-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for preparing antigen-specific t cells from an umbilical cord blood sample
|
CA2987939A1
(en)
|
2015-06-02 |
2016-12-08 |
Sanofi Pasteur Inc. |
Engineered influenza antigenic polypeptides and immunogenic compositions thereof
|
US10954492B2
(en)
|
2015-06-10 |
2021-03-23 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Processes for production and purification of nucleic acid-containing compositions
|
KR20180021874A
(ko)
*
|
2015-06-26 |
2018-03-05 |
바이엘 애니멀 헬스 게엠베하 |
시토졸 dna 감시 분자의 조절 방법
|
PE20240927A1
(es)
|
2015-07-21 |
2024-04-30 |
Pfizer |
Composiciones inmunogenas que comprenden antigenos de sacarido capsular conjugados, kits que las comprenden y sus usos
|
KR20180036765A
(ko)
*
|
2015-07-31 |
2018-04-09 |
바이엘 애니멀 헬스 게엠베하 |
돼지 종에서의 강화된 면역 응답성
|
BR112018005315A2
(pt)
|
2015-09-17 |
2018-10-09 |
Jrx Biotechnology Inc |
abordagens para aprimorar hidratação ou umidificação de pele
|
WO2017059280A1
(en)
|
2015-10-02 |
2017-04-06 |
The University Of North Carolina At Chapel Hill |
Novel pan-tam inhibitors and mer/axl dual inhibitors
|
US10548970B2
(en)
|
2015-10-05 |
2020-02-04 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Human rotavirus G9P[6] strain and use as a vaccine
|
JP7171433B2
(ja)
|
2015-10-30 |
2022-11-15 |
ザ ユナイテッド ステイツ オブ アメリカ, アズ リプレゼンテッド バイ ザ セクレタリー, デパートメント オブ ヘルス アンド ヒューマン サービシーズ |
Her-2発現固形腫瘍の処置のための組成物および方法
|
WO2017085586A1
(en)
|
2015-11-20 |
2017-05-26 |
Pfizer Inc. |
Immunogenic compositions for use in pneumococcal vaccines
|
RU2718663C2
(ru)
|
2016-01-19 |
2020-04-13 |
Пфайзер Инк. |
Противораковые вакцины
|
WO2017189448A1
(en)
|
2016-04-25 |
2017-11-02 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Bivalent immunogenic conjugate for malaria and typhoid
|
WO2017193087A1
(en)
|
2016-05-06 |
2017-11-09 |
Exicure, Inc. |
Liposomal spherical nucleic acid (sna) constructs prsenting antisense oligonucleotides(aso) for specific knockdown of interleukin 17 receptor mrna
|
US11173207B2
(en)
|
2016-05-19 |
2021-11-16 |
The Regents Of The University Of Michigan |
Adjuvant compositions
|
EP3464328A1
(en)
|
2016-06-02 |
2019-04-10 |
Sanofi Pasteur Inc. |
Engineered influenza antigenic polypeptides and immunogenic compositions thereof
|
IL312520A
(en)
|
2016-06-03 |
2024-07-01 |
Sanofi Pasteur Inc |
Modification of transgenic influenza hemagglutinin polypeptides
|
WO2017218339A1
(en)
|
2016-06-13 |
2017-12-21 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Nucleic acids encoding zika virus-like particles and their use in zika virus vaccines and diagnostic assays
|
US10632185B2
(en)
|
2016-07-08 |
2020-04-28 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Chimeric west nile/zika viruses and methods of use
|
US11344615B2
(en)
|
2016-07-08 |
2022-05-31 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Nucleic acids encoding chimeric dengue/Zika viruses optimized for growth and stability in vero cells
|
JP7001686B2
(ja)
|
2016-08-05 |
2022-02-04 |
サノフィ パスツール インコーポレイティッド |
多価肺炎球菌多糖体-タンパク質コンジュゲート組成物
|
JP7001687B2
(ja)
|
2016-08-05 |
2022-02-04 |
サノフィ パスツール インコーポレイティッド |
多価肺炎球菌多糖体-タンパク質コンジュゲート組成物
|
US10172933B2
(en)
|
2016-10-31 |
2019-01-08 |
The United States Of America, As Represented By The Secretary Of Agriculture |
Mosaic vaccines for serotype a foot-and-mouth disease virus
|
PL3570879T3
(pl)
|
2017-01-20 |
2022-06-20 |
Pfizer Inc. |
Kompozycje immunogenne do zastosowania w szczepionkach przeciw pneumokokom
|
US11696954B2
(en)
|
2017-04-28 |
2023-07-11 |
Exicure Operating Company |
Synthesis of spherical nucleic acids using lipophilic moieties
|
EP3655031A1
(en)
|
2017-07-21 |
2020-05-27 |
The U.S.A. as represented by the Secretary, Department of Health and Human Services |
Neisseria meningitidis immunogenic compositions
|
US11235046B2
(en)
|
2017-11-04 |
2022-02-01 |
Nevada Research & Innovation Corporation |
Immunogenic conjugates and methods of use thereof
|
US11116830B2
(en)
|
2017-12-18 |
2021-09-14 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Bacterial polysaccharide-conjugated carrier proteins and use thereof
|
WO2019126371A1
(en)
|
2017-12-19 |
2019-06-27 |
Massachusetts Institute Of Technology |
Antigen-adjuvant coupling reagents and methods of use
|
EP3743107A1
(en)
|
2018-01-22 |
2020-12-02 |
The United States of America, as represented by the Secretary, Department of Health and Human Services |
Broadly protective inactivated influenza virus vaccine
|
SG11202007518RA
(en)
|
2018-02-28 |
2020-09-29 |
Pfizer |
Il-15 variants and uses thereof
|
US11633471B2
(en)
|
2018-03-06 |
2023-04-25 |
Unm Rainforest Innovations |
Compositions and methods for reducing serum triglycerides
|
JP7329529B2
(ja)
|
2018-03-28 |
2023-08-18 |
サノフィ パスツール インコーポレイテッド |
ヘマグルチニンを含む広範に防御的なワクチン組成物を生成する方法
|
EP3773708A2
(en)
|
2018-04-03 |
2021-02-17 |
Sanofi |
Antigenic epstein barr virus polypeptides
|
EP3773703A1
(en)
|
2018-04-03 |
2021-02-17 |
Sanofi |
Antigenic influenza-ferritin polypeptides
|
WO2019195276A1
(en)
|
2018-04-03 |
2019-10-10 |
Sanofi |
Antigenic ospa polypeptides
|
EP3773704A1
(en)
|
2018-04-03 |
2021-02-17 |
Sanofi |
Antigenic respiratory syncytial virus polypeptides
|
JP2021519596A
(ja)
|
2018-04-03 |
2021-08-12 |
サノフイSanofi |
フェリチンタンパク質
|
SG11202010580TA
(en)
|
2018-05-23 |
2020-12-30 |
Pfizer |
Antibodies specific for cd3 and uses thereof
|
CN113286634A
(zh)
|
2018-05-23 |
2021-08-20 |
辉瑞公司 |
对gucy2c特异性的抗体及其用途
|
US11260119B2
(en)
|
2018-08-24 |
2022-03-01 |
Pfizer Inc. |
Escherichia coli compositions and methods thereof
|
KR20210124205A
(ko)
|
2018-12-04 |
2021-10-14 |
더 락커펠러 유니버시티 |
Hiv 백신 면역원
|
WO2020123777A1
(en)
|
2018-12-12 |
2020-06-18 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Recombinant mumps virus vaccine expressing genotype g fusion and hemagglutinin-neuraminidase proteins
|
CA3120922A1
(en)
|
2018-12-12 |
2020-06-18 |
Pfizer Inc. |
Immunogenic multiple hetero-antigen polysaccharide-protein conjugates and uses thereof
|
EP3894429B1
(en)
|
2018-12-14 |
2024-02-21 |
University of Georgia Research Foundation, Inc. |
Crimean-congo hemorrhagic fever virus replicon particles and use thereof
|
US20220370606A1
(en)
|
2018-12-21 |
2022-11-24 |
Pfizer Inc. |
Combination Treatments Of Cancer Comprising A TLR Agonist
|
EP3946446A1
(en)
|
2019-04-02 |
2022-02-09 |
Sanofi |
Antigenic multimeric respiratory syncytial virus polypeptides
|
CA3136278A1
(en)
|
2019-04-10 |
2020-10-15 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
|
WO2021084429A1
(en)
|
2019-11-01 |
2021-05-06 |
Pfizer Inc. |
Escherichia coli compositions and methods thereof
|
CN115397853A
(zh)
|
2019-12-17 |
2022-11-25 |
辉瑞大药厂 |
对cd47、pd-l1具特异性的抗体及其用途
|
BR112022010228A2
(pt)
|
2019-12-17 |
2022-09-06 |
Us Health |
Vacinas de parasita de leishmania viva atenuada com características de segurança aumentadas
|
WO2021165928A2
(en)
|
2020-02-23 |
2021-08-26 |
Pfizer Inc. |
Escherichia coli compositions and methods thereof
|
WO2021173907A1
(en)
|
2020-02-28 |
2021-09-02 |
Sanofi Pasteur, Inc. |
High dose influenza vaccine for pediatric subjects
|
US11213482B1
(en)
|
2020-03-05 |
2022-01-04 |
University of Pittsburgh—Of the Commonwealth System of Higher Educat |
SARS-CoV-2 subunit vaccine and microneedle array delivery system
|
JP2023533793A
(ja)
|
2020-07-17 |
2023-08-04 |
ファイザー・インク |
治療用抗体およびそれらの使用
|
AU2021368151B2
(en)
|
2020-10-27 |
2024-09-05 |
Pfizer Inc. |
Escherichia coli compositions and methods thereof
|
US20240000912A1
(en)
|
2020-11-04 |
2024-01-04 |
Pfizer Inc. |
Immunogenic compositions for use in pneumococcal vaccines
|
JP2023549736A
(ja)
|
2020-11-10 |
2023-11-29 |
ファイザー・インク |
コンジュゲートさせた莢膜糖抗原を含む免疫原性組成物およびその使用
|
US20220202923A1
(en)
|
2020-12-23 |
2022-06-30 |
Pfizer Inc. |
E. coli fimh mutants and uses thereof
|
WO2022147373A1
(en)
|
2020-12-31 |
2022-07-07 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Antibody-guided pcsk9-mimicking immunogens lacking 9-residue sequence overlap with human proteins
|
CA3211240A1
(en)
|
2021-02-19 |
2022-08-25 |
Sanofi Pasteur Inc. |
Meningococcal b recombinant vaccine
|
CN117425668A
(zh)
|
2021-03-16 |
2024-01-19 |
国立大学法人大阪大学 |
SARS-CoV-2病毒特异性滤泡辅助性T细胞Tfh
|
CN117441103A
(zh)
|
2021-03-16 |
2024-01-23 |
国立大学法人大阪大学 |
使用滤泡性t细胞的新型医疗技术
|
EP4346892A2
(en)
|
2021-05-28 |
2024-04-10 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
WO2022249107A2
(en)
|
2021-05-28 |
2022-12-01 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
MX2024000330A
(es)
|
2021-07-16 |
2024-01-25 |
Univ Illinois |
Vacuna universal para virus de influenza en base a la proteina m2 tetramerica incorporada en nanodiscos.
|
EP4384534A1
(en)
|
2021-08-11 |
2024-06-19 |
Sanofi Pasteur, Inc. |
Truncated influenza neuraminidase and methods of using the same
|
WO2023059857A1
(en)
|
2021-10-08 |
2023-04-13 |
Sanofi Pasteur Inc. |
Multivalent influenza vaccines
|
WO2023079113A1
(en)
|
2021-11-05 |
2023-05-11 |
Sanofi |
Hybrid multivalent influenza vaccines comprising hemagglutinin and neuraminidase and methods of using the same
|
KR20240105412A
(ko)
|
2021-11-05 |
2024-07-05 |
사노피 파스퇴르 인크 |
재조합 헤마글루티닌과 뉴라미니다제를 포함하는 다가 인플루엔자 백신 및 이의 사용 방법
|
US20230302112A1
(en)
|
2021-11-05 |
2023-09-28 |
Sanofi |
Respiratory synctial virus rna vaccine
|
KR20240118795A
(ko)
|
2021-11-30 |
2024-08-05 |
사노피 파스퇴르 인크 |
인간 메타뉴모바이러스 바이러스 벡터-기반 백신
|
AR127808A1
(es)
|
2021-11-30 |
2024-02-28 |
Sanofi Pasteur Inc |
Vacunas contra el metapneumovirus humano
|
WO2023111262A1
(en)
|
2021-12-17 |
2023-06-22 |
Sanofi |
Lyme disease rna vaccine
|
IL314243A
(en)
|
2022-01-13 |
2024-09-01 |
Pfizer |
Immunogenic preparations containing conjugates of capsular sugar antigen and their uses
|
WO2023144206A1
(en)
|
2022-01-27 |
2023-08-03 |
Sanofi Pasteur |
Modified vero cells and methods of using the same for virus production
|
WO2023161817A1
(en)
|
2022-02-25 |
2023-08-31 |
Pfizer Inc. |
Methods for incorporating azido groups in bacterial capsular polysaccharides
|
WO2023177579A1
(en)
|
2022-03-14 |
2023-09-21 |
Sanofi Pasteur Inc. |
Machine-learning techniques in protein design for vaccine generation
|
WO2023214082A2
(en)
|
2022-05-06 |
2023-11-09 |
Sanofi |
Signal sequences for nucleic acid vaccines
|
WO2023218322A1
(en)
|
2022-05-11 |
2023-11-16 |
Pfizer Inc. |
Process for producing of vaccine formulations with preservatives
|
WO2024094881A1
(en)
|
2022-11-04 |
2024-05-10 |
Sanofi |
Respiratory syncytial virus rna vaccination
|
WO2024110827A1
(en)
|
2022-11-21 |
2024-05-30 |
Pfizer Inc. |
Methods for preparing conjugated capsular saccharide antigens and uses thereof
|
US20240181028A1
(en)
|
2022-11-22 |
2024-06-06 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
WO2024116096A1
(en)
|
2022-12-01 |
2024-06-06 |
Pfizer Inc. |
Pneumococcal conjugate vaccine formulations
|
WO2024121380A1
(en)
|
2022-12-08 |
2024-06-13 |
Pierre Fabre Medicament |
Vaccinal composition and adjuvant
|
WO2024127215A2
(en)
|
2022-12-13 |
2024-06-20 |
Pfizer Inc. |
Immunogenic compositions and methods for eliciting an immune response against clostridioides (clostridium) difficile
|
WO2024133515A1
(en)
|
2022-12-20 |
2024-06-27 |
Sanofi |
Rhinovirus mrna vaccine
|
WO2024163327A1
(en)
|
2023-01-30 |
2024-08-08 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Epstein-barr virus glycoprotein 42 immunogens for vaccination and antibody discovery
|
WO2024166008A1
(en)
|
2023-02-10 |
2024-08-15 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
US20240299524A1
(en)
|
2023-03-02 |
2024-09-12 |
Sanofi |
Compositions for use in treatment of chlamydia
|